Pharmaceutical Research and Manufacturers of America

Pharmaceutical Research and Manufacturers of America is a prominent trade association and lobbying group representing the country's leading pharmaceutical research and biotechnology companies. Founded in the mid-20th century, it is headquartered in Washington, D.C. and is a major force in shaping health policy, advocating for innovation, and engaging in public discourse on drug pricing and access. The organization's activities span federal and state legislative advocacy, public health initiatives, and media campaigns, often positioning itself at the center of national debates over the Affordable Care Act, Medicare Part D, and intellectual property rights.

History and formation

The organization was established in 1958 through the merger of two earlier associations, the American Drug Manufacturers Association and the Pharmaceutical Manufacturers Association. This consolidation occurred during a period of significant growth for the American pharmaceutical industry following breakthroughs like the development of penicillin and the polio vaccine. Throughout the 1960s and 1970s, it engaged with new regulatory frameworks established by the Kefauver Harris Amendment and the creation of the Medicaid program. A major rebranding in 1994 saw the adoption of its current name, reflecting an increased focus on research-intensive companies amid the rise of biotechnology firms like Genentech and Amgen.

Organization and membership

The association is led by a board of directors comprising executives from member companies, with day-to-day operations managed by President and CEO Stephen J. Ubl. Its membership includes many of the world's largest and most research-intensive pharmaceutical and biotech companies, such as Pfizer, Merck & Co., Johnson & Johnson, and Eli Lilly and Company. Membership is restricted to firms that engage in significant innovative research, with many members also belonging to international counterparts like the International Federation of Pharmaceutical Manufacturers & Associations. The organization maintains a substantial staff of lobbyists, lawyers, and communications professionals, operating primarily from its headquarters in Washington, D.C..

Policy positions and advocacy

A central policy focus is advocating for strong intellectual property protections, including patents and data exclusivity periods under the Hatch-Waxman Act and provisions in international agreements like the TRIPS Agreement. It consistently opposes measures it views as price controls, such as government negotiation in Medicare Part D or importation of drugs from Canada, while supporting market-based solutions. The association was a key architect and supporter of the Medicare Prescription Drug, Improvement, and Modernization Act and has been a significant opponent of elements within the Affordable Care Act related to the Independent Payment Advisory Board. It also engages in state-level advocacy, often challenging legislation in states like California and Vermont.

Key initiatives and programs

The "From Hope to Cures" and "GoBoldly" campaigns are major public-facing initiatives designed to highlight industry innovation and the drug development process. It operates PhRMA Foundation, which provides research grants and fellowships in collaboration with institutions like the University of North Carolina at Chapel Hill and the Mayo Clinic. The organization's "Partnership for Prescription Assistance" program, launched in 2005, aimed to connect patients with patient assistance programs. More recently, it has launched initiatives focused on value assessment frameworks and the ethical use of artificial intelligence in drug discovery, often in partnership with entities like the National Institutes of Health.

Criticism and controversies

The association has faced sustained criticism from lawmakers, patient advocacy groups, and NGOs like Public Citizen and Doctors Without Borders for its lobbying against measures to lower drug prices. Its role in shaping the Medicare Part D legislation, which prohibited government price negotiation, has been a frequent point of contention. High-profile investigations, such as those by the Senate Finance Committee under Senator Chuck Grassley and the House Oversight Committee, have scrutinized its pricing and marketing practices. The organization has also been criticized for its opposition to the Affordable Care Act's biosimilar pathway and for lawsuits challenging transparency laws in states like Nevada.

Category:Pharmaceutical industry trade groups Category:Organizations based in Washington, D.C. Category:Lobbying organizations in the United States